Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients
Experimental and Clinical Endocrinology & Diabetes · 01.06.2024 · 132 (06) · 328-335
DOI: 10.1055/a-2280-3742 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.06.2024. Verfasst von Jie Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, Liver Cirrhosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
To investigate the association between liver fibrosis score and diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM).
Methods
A total of 897 hospitalized patients with T2DM were included in this study. Each patient completed DKD screening. Logistic regression analysis was used to assess the predictive value of non-alcoholic fatty liver disease fibrosis score (NAFLD-FS) and fibrosis-4 (FIB-4) for the occurrence of DKD and risk for DKD progression, respectively.
Results
The prevalence of DKD and risk for its progression significantly increased with increasing NAFLD-FS risk category. DKD prevalence also increased with increasing FIB-4 risk category. Multivariate logistic regression analysis showed that the “high-risk” NAFLD-FS had a significantly higher risk of DKD (odds ratio [OR]: 1.89, 95% confidence interval [CI]: 1.16–3.08) and risk for DKD progression (OR: 2.88, 95% CI: 1.23–6.78), and the “intermediate-risk” FIB-4 had a significantly higher risk of DKD (OR: 1.41, 95% CI: 1.00–1.98). Subgroup analysis showed that the association between NAFLD-FS and FIB-4 and DKD was significant in the female subgroup, whereas the association between the “high-risk” NAFLD-FS and risk for DKD progression was significant in the male subgroup.
Conclusions
NAFLD-FS and FIB-4 are strongly associated with DKD and risk for DKD progression in patients with T2DM. Additionally, sexual dimorphism exists in this association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, 330006, People's Republic of China.
- Queen Mary School, Medical College, Nanchang University, Nanchang 330006, China.
- The Third Clinical Medical School, Medical College, Nanchang University, Nanchang 330006, China.
- Department of Medical Genetics and Cell biology, Medical College of Nanchang University, Nanchang, 330006, People's Republic of China.
- Jiangxi Clinical Research Center for Endocrine and Metabolic Disease, Nanchang, Jiangxi, 330006, People's Republic of China.
- Jiangxi Branch of National Clinical Research Center for Metabolic Disease, Nanchang, Jiangxi, 330006, People's Republic of China.
Zitieren
APA
Zhang, J., Chen, S., Tian, Z., Cao, J., Jiao, Y., Wang, B., Feng, S., Luo, Z., Zhang, Q., Deng, Y., Cai, W., & Xu, J. (2024). Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients. Experimental and Clinical Endocrinology & Diabetes, 132(06), 328-335. https://doi.org/10.1055/a-2280-3742
Vancouver
Zhang J, Chen S, Tian Z, Cao J, Jiao Y, Wang B, et al. Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients. Experimental and Clinical Endocrinology & Diabetes. 2024;132(06):328-335. doi:10.1055/a-2280-3742
BibTeX
@article{Zhang2024,
author = {Zhang, Jie and Chen, Shen and Tian, Zhendong and Cao, Jiarui and Jiao, Yijie and Wang, Bangqi and Feng, Shenghui and Luo, Zhanpeng and Zhang, Qingfang and Deng, Yuanyuan and Cai, Wei and Xu, Jixiong},
title = {Association Between Liver Fibrosis Score and Diabetic Kidney Disease: A Retrospective Cross-Sectional Study of Hospitalized Patients},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {06},
pages = {328--335},
doi = {10.1055/a-2280-3742}
}
EUVIMED